The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
3-(5-(5-bromo-2-hydroxy-3-methoxybenzylidene)-4-oxo-4,5-dihydrothiazol-2-ylamino)benzoic acid ID: ALA572150
PubChem CID: 135697783
Max Phase: Preclinical
Molecular Formula: C18H13BrN2O5S
Molecular Weight: 449.28
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc(Br)cc(/C=C2/SC(Nc3cccc(C(=O)O)c3)=NC2=O)c1O
Standard InChI: InChI=1S/C18H13BrN2O5S/c1-26-13-8-11(19)5-10(15(13)22)7-14-16(23)21-18(27-14)20-12-4-2-3-9(6-12)17(24)25/h2-8,22H,1H3,(H,24,25)(H,20,21,23)/b14-7+
Standard InChI Key: UYDUEDPSEYLRAT-VGOFMYFVSA-N
Molfile:
RDKit 2D
27 29 0 0 0 0 0 0 0 0999 V2000
-0.0667 -3.9795 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7584 -3.9795 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.0152 -4.7637 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3458 -5.2505 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-0.3192 -4.7637 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7252 -5.1755 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.4405 -4.7643 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1532 -5.1794 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8680 -4.7689 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8701 -3.9430 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1514 -3.5291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4395 -3.9420 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5837 -5.1852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5817 -6.0102 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.2993 -4.7744 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.4875 -3.2586 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.0376 -5.1713 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7491 -4.7534 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7390 -3.9304 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4495 -3.5125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1682 -3.9198 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1717 -4.7491 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4605 -5.1632 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4430 -2.6875 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
-2.4624 -5.9882 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-3.8879 -5.1589 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.6007 -4.7435 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6 7 1 0
13 14 1 0
13 15 2 0
9 13 1 0
2 3 2 0
1 16 2 0
7 8 2 0
5 17 2 0
3 4 1 0
17 18 1 0
8 9 1 0
18 19 2 0
4 5 1 0
19 20 1 0
9 10 2 0
20 21 2 0
5 1 1 0
21 22 1 0
10 11 1 0
22 23 2 0
23 18 1 0
1 2 1 0
20 24 1 0
11 12 2 0
23 25 1 0
12 7 1 0
22 26 1 0
3 6 1 0
26 27 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 449.28Molecular Weight (Monoisotopic): 447.9729AlogP: 3.94#Rotatable Bonds: 4Polar Surface Area: 108.22Molecular Species: ACIDHBA: 6HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 4.74CX Basic pKa: ┄CX LogP: 3.62CX LogD: 0.99Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.61Np Likeness Score: -1.12
References 1. Gupta RK, Thakur TS, Desiraju GR, Tyagi JS.. (2009) Structure-based design of DevR inhibitor active against nonreplicating Mycobacterium tuberculosis., 52 (20): [PMID:19827833 ] [10.1021/jm900358q ] 2. Al-Asri J, Fazekas E, Lehoczki G, Perdih A, Görick C, Melzig MF, Gyémánt G, Wolber G, Mortier J.. (2015) From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors., 23 (20): [PMID:26395057 ] [10.1016/j.bmc.2015.09.007 ]